Literature DB >> 27734772

Flurbiprofen 8.75 mg lozenges for treating sore throat symptoms: a randomized, double-blind, placebo-controlled study.

Bernard P Schachtel1, Adrian Shephard2, Timothy Shea3, Kathleen Sanner1, Laurie Savino1, Jeanne Rezuke1, Emily Schachtel1, Sue Aspley2.   

Abstract

AIM: This study assessed multiple doses of flurbiprofen 8.75 mg lozenges for the relief of three prominent symptoms of acute pharyngitis: pain intensity (primary end point), difficulty swallowing and swollen throat. PATIENTS &
METHODS: A total of 204 patients (102 in each group) with confirmed pharyngitis (onset ≤4 days) were randomly assigned to take up to five flurbiprofen or placebo lozenges every 3-6 h, for 7 days. Using validated rating scales (sore throat pain intensity, difficulty swallowing and swollen throat) patients rated their symptoms for the duration of the study.
RESULTS: Over the first 24 h, patients treated with flurbiprofen lozenges reported significantly greater reductions in sore throat pain (47%) as well as difficulty swallowing (66%) and swollen throat (40%) compared with placebo (all p < 0.05).
CONCLUSION: Multiple doses of flurbiprofen lozenges provide effective relief of sore throat pain intensity as well as difficulty swallowing and swollen throat.

Entities:  

Keywords:  NSAID; acute pharyngitis; analgesia; flurbiprofen; respiratory tract infection; sore throat; streptococcal infection

Mesh:

Substances:

Year:  2016        PMID: 27734772     DOI: 10.2217/pmt-2015-0001

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  4 in total

1.  Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: a randomized, non-inferiority trial in the Russian Federation.

Authors:  Eugenia Radkova; Natalia Burova; Valeria Bychkova; Robert DeVito
Journal:  J Pain Res       Date:  2017-07-06       Impact factor: 3.133

2.  Improvements in throat function and qualities of sore throat from locally applied flurbiprofen 8.75 mg in spray or lozenge format: findings from a randomized trial of patients with upper respiratory tract infection in the Russian Federation.

Authors:  Natalia Burova; Valeria Bychkova; Adrian Shephard
Journal:  J Pain Res       Date:  2018-06-01       Impact factor: 3.133

3.  Ectoine lozenges in the treatment of acute viral pharyngitis: a prospective, active-controlled clinical study.

Authors:  Van-Anh Dao; Sabrina Overhagen; Andreas Bilstein; Carina Kolot; Uwe Sonnemann; Ralph Mösges
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-09       Impact factor: 2.503

Review 4.  Locally Delivered Flurbiprofen 8.75 mg for Treatment and Prevention of Sore Throat: A Narrative Review of Clinical Studies.

Authors:  Ferdinandus de Looze; Adrian Shephard; Adam B Smith
Journal:  J Pain Res       Date:  2019-12-27       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.